Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Aspirin for primary prevention of cardiovascular disease.
TL;DR: There is lack of evidence that the benefits outweigh the adverse events with continuous aspirin use in primary CVD prevention, and Physicians should continuously be trained to calculate their patients CVD risk, and concomitant strategies be emphasized.
Journal ArticleDOI
Statins for primary prevention of cardiovascular disease: The benefits outweigh the risks
TL;DR: The evidence for statins in primary prevention is reviewed and the cardiovascular benefits of statins for primary prevention generally far outweigh the reported harms.
Journal ArticleDOI
General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study.
TL;DR: The majority of older people with chronic diseases are prescribed multiple medicines resulting in polypharmacy, and the extrapolation of the ‘single disease model’ represented by disease‐specific guidelines is a major driver for polyphARMacy.
Journal ArticleDOI
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Ezimamaka Ajufo,Colby Ayers,Rebecca Vigen,Parag H. Joshi,Anand Rohatgi,James A. de Lemos,Amit Khera +6 more
TL;DR: Higher CAC is associated with both ASCVD and bleeding events, with a stronger association with ASCVD, and a high CAC score identifies individuals estimated to derive net benefit from primary prevention aspirin therapy from those who would not, but only in the setting of lower bleeding risk and estimated ASCVD risk that is not low.
Journal ArticleDOI
Salicylate Functions as an Efflux Pump Inducer and Promotes the Emergence of Fluoroquinolone-Resistant Campylobacter jejuni Mutants
TL;DR: Results indicate that in Campylobacter, salicylate inhibits the binding of CmeR to the promoter DNA and induces expression of cmeABC, resulting in decreased susceptibility to antibiotics and in increased emergence of fluoroquinolone-resistant mutants under selection pressure.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.